Centene’s Q3 results and improved full-year outlook were broadly in line with the company’s stated business trends, while shares rose 1.0% after the earnings release. Medicare outperformed expectations, but Medicaid remains dependent on continued rate alignment as membership declines and eligibility changes progress.
Centene shares surged 24.1% following a significant first quarter outperformance, driven by upside in both adjusted EPS and margin improvement across core Medicaid and Medicare businesses. Management raised full-year 2026 adjusted EPS guidance above the prior target, citing operational execution and favorable medical trends.
Centene Corporation reported strong third quarter 2025 results, with adjusted EPS of $0.50 exceeding expectations, driven by improved Medicaid performance and better-than-anticipated net investment income. The company raised its full-year adjusted EPS forecast to at least $2.